Mechanisms of resistance to azacitidine in human leukemia cell lines

Experimental Hematology

Volumn 42, Issue 4, 2014, Pages

  Sripayap, Piyanuch ^a   Nagai, Tadashi ^a   Uesawa, Mitsuyo ^a   Kobayashi, Hiroyuki ^a   Tsukahara, Tomonori ^a   Ohmine, Ken ^a   Muroi, Kazuo ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BCL2L10 PROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; POINT MUTATION; PRIORITY JOURNAL; URIDINE CYTIDINE KINASE 2 GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; G2 PHASE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; POINT MUTATION; URIDINE KINASE;

EID: 84899128559     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.12.004     Document Type: Article

References (37)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16:6-21.
2. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
3. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17:1813-1819.
4. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
5. Baylin S.B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005, 2(Suppl 1):S4-S11.
6. Figueroa M.E., Skrabanek L., Li Y., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114:3448-3458.
7. Christman J.K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21:5483-5495.
8. Kuykendall J.R. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother 2005, 39:1700-1709.
9. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000, 249:135-164.
10. Lubbert M., Wijermans P., Kunzmann R., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001, 114:349-357.
11. Sudan N., Rossetti J.M., Shadduck R.K., et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006, 107:1839-1843.
12. Keating G.M. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2009, 69:2501-2518.
13. Ravandi F., Issa J.P., Garcia-Manero G., et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009, 115:5746-5751.
14. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
15. Santos F.P., Kantarjian H., Garcia-Manero G., Issa J.P., Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 2010, 10:9-22.
16. van der Helm L.H., Veeger N.J., Kooy M.V., et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res 2013, 37:877-882.
17. Prebet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
18. Damaraju V.L., Damaraju S., Young J.D., et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003, 22:7524-7536.
19. Kong W., Engel K., Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004, 5:63-84.
20. Pastor-Anglada M., Molina-Arcas M., Casado F.J., et al. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004, 18:385-393.
21. Rius M., Stresemann C., Keller D., et al. Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther 2009, 8:225-231.
22. Kroep J.R., Loves W.J., van der Wilt C.L., et al. Pretreatment deoxycytidine kinase levels predict invivo gemcitabine sensitivity. Mol Cancer Ther 2002, 1:371-376.
23. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
24. Cluzeau T., Robert G., Mounier N., et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 2012, 3:490-501.
25. Mahfouz R.Z., Jankowska A., Ebrahem Q., et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res 2013, 19:938-948.
26. Collins S.J., Gallo R.C., Gallagher R.E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977, 270:347-349.
27. Tsuchiya S., Yamabe M., Yamaguchi Y., et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980, 26:171-176.
28. Miyoshi T., Nagai T., Kikuchi S., et al. Cloning and characterization of ahuman BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib. Exp Hematol 2007, 35:1358-1365.
29. Lassar A.B., Davis R.L., Wright W.E., et al. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins invivo. Cell 1991, 66:305-315.
30. Uchida S., Yoshioka K., Kizu R., et al. Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation. Cancer Res 2009, 69:6438-6444.
31. Zhu N., Shao Y., Xu L., Yu L., Sun L. Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells. Mol Biol Rep 2009, 36:2075-2085.
32. Moon D.O., Kim M.O., Choi Y.H., et al. Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. Cancer Lett 2010, 288:204-213.
33. Yoshida K., Nagai T., Ohmine K., et al. Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells. Biochem Pharmacol 2011, 82:1884-1890.
34. Cluzeau T., Robert G., Puissant A., et al. Azacitidine-resistant SKM1 myeloid cells are defective for azacitidine-induced mitochondrial apoptosis and autophagy. Cell Cycle 2011, 10:2339-2343.
35. Marcucci G., Silverman L., Eller M., Lintz L., Beach C.L. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J. Clin. Pharmacol 2005, 45:597-602.
36. Murata D., Endo Y., Obata T., et al. A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides. Drug Metab Dispos 2004, 32:1178-1182.
37. Flasshove M., Strumberg D., Ayscue L., et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994, 8:780-785.